Vaxart (VXRT) Stock Price, News & Analysis

Company Overview

Vaxart, Inc. is a clinical-stage biotechnology company developing vaccines designed to be administered orally in tablet form rather than by injection. The company’s platform is intended to stimulate immune responses in the nose, mouth and gastrointestinal tract, in addition to systemic immunity, with the goal of improving vaccine administration and potentially limiting the spread of respiratory and enteric infections.

Vaxart’s pipeline has included oral vaccine candidates for norovirus, seasonal influenza and coronavirus infections. Its programs use recombinant vaccine technologies delivered through an oral tablet, and the company has evaluated candidates in clinical studies. Vaxart does not have an approved commercial product and remains focused on research, development and clinical testing.

The company traces its corporate history to Vaxart, which became the operating business of Aviragen Therapeutics before Aviragen adopted the Vaxart name in 2018. Vaxart is based in South San Francisco, California, and its activities are primarily centered on developing vaccine candidates for potential use in the United States and international markets. Steven Lo has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $0.47 to $0.50
• 50-Day Range: $0.45 to $0.60
• 52-Week Range: $0.31 to $0.84
• Volume: 124,576 shs
• Average Volume: 508,441 shs
• Market Capitalization: $119.90 million
• P/E Ratio: 3.08
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Vaxart Stock Analysis - MarketRank™

Vaxart scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Vaxart has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vaxart has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vaxart are expected to decrease in the coming year, from ($0.68) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxart is 3.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxart is 3.06, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.23.

Price to Book Value per Share Ratio

Vaxart has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.98% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaxart has recently decreased by 0.95%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxart does not currently pay a dividend.

Dividend Growth

Vaxart does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Vaxart has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vaxart this week, compared to 1 article on an average week.

Search Interest

Only 8 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Vaxart to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxart insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.80% of the stock of Vaxart is held by insiders.

Percentage Held by Institutions

18.05% of the stock of Vaxart is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VXRT
• Previous Symbol: NASDAQ:NABI
• CIK: 72444
• Web: www.vaxart.com
• Phone: (650) 550-3500
• Fax: 650-871-8580
• Employees: 120
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): $0.16
• Trailing P/E Ratio: 3.07
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $16.33 million
• Net Margins: 15.88%
• Pretax Margin: 16.05%
• Return on Equity: 53.04%
• Return on Assets: 20.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.60
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $47.40 million
• Price / Sales: 2.52
• Cash Flow: $0.10 per share
• Price / Cash Flow: 4.75
• Book Value: $0.37 per share
• Price / Book: 1.33

Miscellaneous

• Outstanding Shares: 243,701,000
• Free Float: 236,877,000
• Market Cap: $119.61 million
• Optionable: No Data
• Beta: 1.06